New Noninvasive Method of Intracranial Pressure Monitoring

Researchers from Klinikum Stuttgart and the University of Erlangen, Germany, report preliminary findings that show a noninvasive method of monitoring intracranial pressure (ICP) that could rival the gold standards of invasive intraventricular and intraparenchymal monitoring. To date no noninvasive method of ICP monitoring has proved adequate to replace invasive ones. The new noninvasive monitoring device uses advanced signal analysis algorithms to evaluate properties of acoustic signals that pass through the brain in order to determine ICP values. It is described in the article "Evaluation of a novel noninvasive ICP monitoring device in patients undergoing invasive ICP monitoring: preliminary results," by Oliver Ganslandt, M.D., and colleagues.

Normally human intracranial pressure (ICP) is 20 mm Hg or lower, but in the presence of brain disease or traumatic head injury, brain tissues may swell or cerebrospinal fluid - the liquid that surrounds and protects the brain - may increase in volume, causing ICP to increase. Increased ICP can cause serious symptoms and sometimes even death. Continuous monitoring of ICP in critical-care patients provides clinicians with the knowledge of whether and when action must be taken to decrease ICP.

To perform invasive ICP monitoring a hole must first be drilled in the patient's skull. A catheter is then inserted into brain tissue (parenchyma) or into a ventricle (a space within the brain that contains cerebrospinal fluid). Sensors in the catheter continuously measure ICP. Intraventricular monitoring is especially useful. An intraventricular catheter can be used both to monitor ICP and to reduce this pressure when it is too high by intermittently extracting excess cerebrospinal fluid.

Intraparenchymal and intraventricular monitoring are gold standards of ICP measurement. However, the procedures required to measure ICP with these methods are invasive. They require opening the skull and carry risks such as bleeding, infection, and damage to brain tissue.

The researchers propose use of an alternative noninvasive ICP monitoring system. They describe the HS-1000 device (HeadSense Medical, Ltd), which emits 6-second-long bursts of sound (66 dB) near one ear. The acoustic signals pass throughout the cranium and, along with physiological brain sounds, are detected by receiving sensors located in the opposite ear. Advanced signal analysis algorithms are used to evaluate properties of the acoustic signals to determine ICP values. Data corresponding to the 6-second epoch are recorded and displayed on the device monitor. The HS-1000 monitoring system can be used continuously, with repeated 6-second epochs, to maintain a constant evaluation of ICP.

The researchers tested the new noninvasive ICP monitoring tool in 14 patients receiving treatment for traumatic brain injury and/or subarachnoid hemorrhage in an intensive care unit. Invasive intraventricular or intraparenchymal monitoring of the patients' conditions was already in place. The researchers then compared ICP values obtained using the noninvasive HS-1000 device with ICP values obtained using an invasive (intraventricular or intraparenchymal) monitoring system.

A comparison of 2543 data points of continuous ICP monitoring showed a strong association between ICP values obtained using noninvasive and invasive methods. Differences in mean ICP values were +/- 3 mm Hg in 63% of data-paired readings and +/- 5 mm Hg in 85% of data-paired readings. The authors point out that similar differences have been found in studies comparing the two invasive methods (intraventricular and intraparenchymal).

The sensitivity and specificity of noninvasive ICP monitoring were determined to be 0.7541 and 0.8887, respectively. Overall, the findings show a good correlation between ICP values obtained using noninvasive and invasive methods of monitoring.

Although this study is preliminary and further investigation is warranted, the authors show that the HS-1000 ICP system provides useful information on normal and elevated ICP values. The authors suggest that use of the device could protect patients from infection and hemorrhage--potential risks of invasive ICP monitoring - and also could aid clinicians in deciding when invasive ICP monitoring may be appropriate.

When asked about the study, Dr. Ganslandt said, "The first results look promising, but further refinements in the algorithm will be necessary to allow a reliable clinical application."

Ganslandt O, Mourtzoukos S, Stadlbauer A, Sommer B, Rammensee R.
Evaluation of a novel noninvasive ICP monitoring device in patients undergoing invasive ICP monitoring: preliminary results.
Journal of Neurosurgery, published online, ahead of print, August 8, 2017; DOI: 10.3171/2016.11.JNS152268.

Most Popular Now

Is AI in Medicine Playing Fair?

As artificial intelligence (AI) rapidly integrates into health care, a new study by researchers at the Icahn School of Medicine at Mount Sinai reveals that all generative AI models may...

Generative AI's Diagnostic Capabili…

The use of generative AI for diagnostics has attracted attention in the medical field and many research papers have been published on this topic. However, because the evaluation criteria were...

AI Tool can Track Effectiveness of Multi…

A new artificial intelligence (AI) tool that can help interpret and assess how well treatments are working for patients with multiple sclerosis (MS) has been developed by UCL researchers. AI uses...

New System for the Early Detection of Au…

A team from the Human-Tech Institute-Universitat Politècnica de València has developed a new system for the early detection of Autism Spectrum Disorder (ASD) using virtual reality and artificial intelligence. The...

Diagnoses and Treatment Recommendations …

A new study led by Prof. Dan Zeltzer, a digital health expert from the Berglas School of Economics at Tel Aviv University, compared the quality of diagnostic and treatment recommendations...

Dr Jason Broch Joins the Highland Market…

The Highland Marketing advisory board has welcomed a new member - Dr Jason Broch, a GP and director with a strong track record in the NHS and IT-enabled transformation. Dr Broch...

Surrey and Sussex Healthcare NHS Trust g…

Surrey and Sussex Healthcare NHS Trust has marked an important milestone in connecting busy radiologists across large parts of South East England, following the successful go live of Sectra's enterprise...

DMEA 2025 Ends with Record Attendance an…

8 - 10 April 2025, Berlin, Germany. DMEA 2025 came to a successful close with record attendance and an impressive program. 20,500 participants attended Europe's leading digital health event over the...